Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Independent Data Monitoring Committee Completed Its Prespecified Review Of Interim Safety Data In Phio Pharmaceuticals’s Phase 1B Trial Of Ph-762 For Advanced Melanoma, Recommending The Study To Continue Without Modification.

PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells. Decreasing the expression of PD-1 increases the capacity of T

PHIO